Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs.

Both studies also found that pharmacy costs contributed to the majority of total healthcare costs, and they also found lower pharmacy costs among those treated with ibrutinib compared with acalabrutinib, though the difference did not reach statistical significance in those studies.

also in 111,027 other papers